Health Care • Biotechnology: Pharmaceutical Preparations
$3.49 ▲ +0.09
(+2.65%)
MKT CAP: $5.7M • VOL: 59.1K
52W L $3 52W H $28
SCNX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $431.6K | $136.6K | $1.4M |
| YoY Revenue Growth % | +215.9% | -90.0% | — |
| Gross Profit | $331.5K | $6.0K | — |
| Gross Margin % | 76.8% | 4.4% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$42.6M | -$14.7M | -$4.4M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$41.5M | $13.6M | -$17.8M |
| EBITDA (Normalized) | — | -$14.7M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$13.4M | -$14.3M | -$2.2M |
| Capital Expenditures (CapEx) | — | $12.0K | — |
| Free Cash Flow (FCF) | -$13.4M | -$14.3M | -$2.2M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -14.7% | — |
| Cash & Short-Term Equivalents | $6.7M | $308.1K | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $70.1M | $79.1M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR SCNX.